Millie Nelson

Eli Lilly expands its pain pipeline again through the acquisition of 4E Therapeutics for an undisclosed price. Millie Nelson,Senior Editor, Partnering and Investment,BioXconomy The deal comes at a time where the medical community continues its search for effective alternatives to opioid-based treatments. Lilly acquired non-opioid pain startupSiteOne in May 2025 for up to $1 billion.

The biotech giant moves to strengthen its immunology portfolio with the acquisition of San Diego-based small molecule specialist. Millie Nelson,Senior Editor, Partnering and Investment,BioXconomy The deal is valued at up to $1 billion and marks a strategic investment in Biogen's pipeline diversification efforts. Biogen will provide an undisclosed upfront payment to RayThera's shareholders. Most of the $1 billion total value is tied to future clinical and regulatory milestone achievements.

The collaboration centers on discovering and developing T cell-engaging multispecific antibodies.AbCellera will perform discovery and early-stage research activities for two initial programs. There is also a commitment to launch a third discovery program within 12 months. Jazz receives exclusive options on each research program and, upon exercising those options and paying associated fees, will gain worldwide rights to develop and commercialize the resulting therapeutic antibodies.